enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
enGene Trading Up 0.6 %
Shares of enGene stock opened at $6.50 on Friday. enGene Holdings Inc. has a 1 year low of $4.42 and a 1 year high of $43.00. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $287.08 million, a PE ratio of -3.78 and a beta of -0.68. The firm’s 50 day moving average is $6.82 and its 200 day moving average is $10.53.
enGene (NASDAQ:ENGN – Get Free Report) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities research analysts forecast that enGene Holdings Inc. will post -1.64 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Research Report on ENGN
Hedge Funds Weigh In On enGene
Large investors have recently bought and sold shares of the company. Altitude Crest Partners Inc. bought a new stake in shares of enGene during the first quarter worth about $2,039,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at approximately $4,715,000. Omega Fund Management LLC acquired a new stake in enGene during the 4th quarter worth approximately $10,441,000. Logos Global Management LP grew its holdings in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in enGene in the 1st quarter valued at approximately $17,095,000. 64.16% of the stock is currently owned by institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Recommended Stories
- Five stocks we like better than enGene
- The Role Economic Reports Play in a Successful Investment Strategy
- When Is the Best Time to Invest in Mutual Funds?
- How Technical Indicators Can Help You Find Oversold Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- Quiet Period Expirations Explained
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.